News

According to HMRC, sugar tax receipts for 2019 were £251 million, representing an increase of around £100 million from 2018.

The drug can be self-administered by injection under the skin at multiple dosing options.

On the news, Kadcyla in this setting is now approved in 27 countries worldwide.

Currently, the treatment is not recommended for use in severe active lupus nephritis anywhere in the world because it has not been previously evaluated in these patients.

The project marks the first time that a viral vaccine programme using this platform will be tested in the treatment of non-small cell lung cancer.

Despite the setback, the company believes “the trial demonstrated that Brukinsa is a highly potent BTK inhibitor that has clinical benefit and trends toward increased response quality.”

On the news, LEO Pharma plans to submit marketing authorisation applications for the drug to regulatory agencies in 2020.

Made up of fibre-optics encased within a fine needle, the probe can look for cancer under the skin’s surface in areas such as the neck.

The new operational area provides additional capacity for GMP-compliant manufacturing services for improved supply chain management.

The approval marks the drug as the first and only oral treatment approved by the FDA in three distinct types of advanced prostate cancer.

The discovery is important as there is currently no cure for MND, and treatment options are limited.

The company will continue to to invest in respiratory medicines with in-market products Xolair (omalizumab) and other Phase III investigational products, QVM149 and QMF149.

The recommendations bring the total count for the year to 66.